Trial Profile
Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery Macroaneurysms
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Aug 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Retinal oedema
- Focus Adverse reactions
- 06 Aug 2019 Planned End Date changed from 1 Aug 2018 to 1 Feb 2020.
- 06 Aug 2019 Planned primary completion date changed from 1 Aug 2018 to 1 Feb 2020.
- 06 Aug 2019 Status changed from recruiting to active, no longer recruiting.